Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
88.78
+2.48 (2.87%)
At close: Mar 9, 2026, 4:00 PM EDT
88.75
-0.03 (-0.03%)
After-hours: Mar 9, 2026, 4:54 PM EDT
Mirum Pharmaceuticals Revenue
In the year 2025, Mirum Pharmaceuticals had annual revenue of $521.31M with 54.74% growth. Mirum Pharmaceuticals had revenue of $148.93M in the quarter ending December 31, 2025, with 49.81% growth.
Revenue (ttm)
$521.31M
Revenue Growth
+54.74%
P/S Ratio
10.28
Revenue / Employee
$1,401,376
Employees
372
Market Cap
5.36B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 1.73B |
| Caris Life Sciences | 812.03M |
| Protagonist Therapeutics | 46.02M |
| CG Oncology | 4.04M |
| CRISPR Therapeutics AG | 3.51M |
MIRM News
- 4 days ago - Mirum Pharmaceuticals Provides AZURE Clinical Program Update for brelovitug in Chronic Hepatitis Delta Virus - Business Wire
- 12 days ago - Mirum Pharmaceuticals, Inc. (MIRM) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2025 Results and Provides Business Update - Business Wire
- 14 days ago - Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 19 days ago - Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026 - Business Wire
- 27 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC) - Business Wire